Mebutamate

Summary

Mebutamate (CHEMBL1200922) is an approved small molecule (ATC N05BC04); indicated across 1 condition including anxiety.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05BC04
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 232.28 Da · C10H20N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200922
Name	Mebutamate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6151
ATC	N05BC04
Molecular formula	C10H20N2O4
Molecular weight	232.28
InChIKey	LEROTMJVBFSIMP-UHFFFAOYSA-N

SMILES: CCC(C)C(C)(COC(=O)N)COC(=O)N

IUPAC name: [2-(carbamoyloxymethyl)-2,3-dimethylpentyl] carbamate

Also known as: Axiten, Butatensin, Capla, Carbuten, Dicamoylmethane, Dormate, Encapla, Ipotensivo, Mebutamat, Mebutamate, Mebutamato, Mebutina

Patent coverage: 412 distinct patent families (1,339 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
anxiety	4	MONDO:0011918	EFO:0005230

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04886297	PHASE3	COMPLETED	A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder
NCT02827188	Not specified	COMPLETED	Cognitive Restructuring in ADHD: Functional Training

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).